Skip to content
DataLookout
Menu

NCT07536061

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 4 → 8 locations
  2. Notable Eligibility criteria expanded, about 9 words
    • Study sites: 4 to 5
  3. Minor Study sites: 2 to 4v3
  4. Notable Recruitment opened
    • Start date changed from estimate of May 5, 2026 to May 12, 2026
    • Site details revised at 2 of 2 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)
Timeframe: Baseline through Week 24

Secondary (3)

Plasma Concentration of SRP-1005
Urine Concentration of SRP-1005
Cerebrospinal Fluid Concentration of SRP-1005

Arms and interventions

Cohort 1: SRP-1005 Dose 1Experimental

Participants will receive SRP-1005 or placebo.

Cohort 2: SRP-1005 Dose 2Experimental

Participants will receive SRP-1005 or placebo.

Cohort 3: SRP-1005 Dose 3Experimental

Participants will receive SRP-1005 or placebo.

Cohort 4: SRP-1005 Dose 4Experimental

Participants will receive SRP-1005 or placebo.

Drugs: SRP-1005, Placebo

Sites

8 sites in 5 countries

United Kingdom 3, Australia 2, New Zealand 1, South Korea 1, Switzerland 1